{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:43:20Z","timestamp":1777333400672,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["CSA2016S-1618"],"award-info":[{"award-number":["CSA2016S-1618"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004441","name":"Styrelsen f\u00f6r Internationellt Utvecklingssamarbete","doi-asserted-by":"publisher","award":["CSA2016S-1618"],"award-info":[{"award-number":["CSA2016S-1618"]}],"id":[{"id":"10.13039\/100004441","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Poverty"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>In 2018, Kenya introduced triple-drug therapy with ivermectin, diethylcarbamazine, albendazole (IDA) through mass drug administration (MDA) to accelerate the elimination of lymphatic filariasis (LF). This community-based surveillance study assessed the safety and effectiveness of IDA-MDA in reducing LF-antigenemia prevalence and circulating filarial antigens (CFA) clearance among LF infected individuals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A total of 8928 residents in Mombasa, Kenya, were screened for CFA using the Filarial Test Strip: 3464 were screened in 2018 and 5464 in 2021 after two annual IDA-MDA rounds. CFA-positive individuals in 2021 were re-tested at two and four months of post-MDA for CFA-clearance rates. Adverse events (AEs) associated with IDA-MDA were monitored via door-to-door visits on days 1, 2, and 7 post-MDA to document the incidence, type and risk factors. Efficacy outcomes included post-MDA LF-antigenemia prevalence reduction after two rounds of annual MDA and CFA clearance rate. Chi-square test compared proportions, and logistic regression analysis identified AE predictors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>LF antigenemia prevalence significantly decreased from 1.39% (<jats:italic>n<\/jats:italic>\u2009=\u200948) in 2018 to 0.66% (<jats:italic>n<\/jats:italic>\u2009=\u200936) in 2021 [<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001; 95% confidence interval (<jats:italic>CI<\/jats:italic>) for difference in proportions: 0.003\u20130.012]. CFA clearance rates were 63.2% (12\/19, 95% <jats:italic>CI:<\/jats:italic> 41.0\u201380.1%) at 2\u00a0months and 68.4% (13\/19, 95% <jats:italic>CI:<\/jats:italic> 46.0\u201386.6%) at 4\u00a0months post-MDA. Among 53 CFA-positive individuals monitored, the cumulative 7-day AE incidence was 37.7% (95% <jats:italic>CI:<\/jats:italic> 25.6\u201351.7), higher than the general population\u2019s 27.3% (95% <jats:italic>CI:<\/jats:italic> 26.4\u201328.2). Common AEs included nausea (11.3%), diarrhea (11.3%), abdominal pain (7.6%), and headache (5.7%). Risk factors for AEs included age, overweight status, concomitant medication use, chronic illness, and fasting before MDA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Triple therapy with IDA is safe and well-tolerated, with some mild-to-moderate and transient adverse events among LF-infected individuals. The high incidence of AEs highlights the need for safety monitoring during MDA. The significant reductions in LF antigenemia prevalence and high CFA clearance rates underscore IDA's effectiveness in reducing LF transmission, positioning it as a key strategy for eliminating LF as a public health problem by 2030.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s40249-025-01282-z","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T10:19:51Z","timestamp":1740392391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and effectiveness of triple-drug therapy with ivermectin, diethylcarbamazine, and albendazole in reducing lymphatic filariasis prevalence and clearing circulating filarial antigens in Mombasa, Kenya"],"prefix":"10.1186","volume":"14","author":[{"given":"Christabel","family":"Khaemba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sammy M.","family":"Njenga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wyckliff P.","family":"Omondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvis","family":"Kirui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Oluka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastacia","family":"Guantai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9788-0790","authenticated-orcid":false,"given":"Eleni","family":"Aklillu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"1282_CR1","unstructured":"Lymphatic filariasis. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lymphatic-filariasis. Accessed 15 Oct 2024."},{"key":"1282_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13071-018-2655-5","volume":"11","author":"J Cano","year":"2018","unstructured":"Cano J, Basanez MG, O\u2019Hanlon SJ, Tekle AH, Wanji S, Zoure HG, et al. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns. Parasit Vectors. 2018;11:70.","journal-title":"Parasit Vectors"},{"key":"1282_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003319","volume":"8","author":"KD Ramaiah","year":"2014","unstructured":"Ramaiah KD, Ottesen EA. Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease. PLoS Negl Trop Dis. 2014;8: e3319.","journal-title":"PLoS Negl Trop Dis"},{"key":"1282_CR4","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1186\/s13071-015-1166-x","volume":"8","author":"P Moraga","year":"2015","unstructured":"Moraga P, Cano J, Baggaley RF, Gyapong JO, Njenga SM, Nikolay B, et al. Modelling the distribution and transmission intensity of lymphatic filariasis in sub-Saharan Africa prior to scaling up interventions: integrated use of geostatistical and mathematical modelling. Parasit Vectors. 2015;8:560.","journal-title":"Parasit Vectors"},{"key":"1282_CR5","unstructured":"Preventive chemotherapy in human helminthiasis. Coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers. https:\/\/www.who.int\/publications\/i\/item\/9241547103. Accessed 5 Sep 2024."},{"key":"1282_CR6","doi-asserted-by":"publisher","first-page":"e1186","DOI":"10.1016\/S2214-109X(20)30286-2","volume":"8","author":"Local Burden of Disease Neglected Tropical Diseases C","year":"2020","unstructured":"Local Burden of Disease Neglected Tropical Diseases C. The global distribution of lymphatic filariasis, 2000\u201318: a geospatial analysis. Lancet Glob Health. 2020;8:e1186\u201394.","journal-title":"Lancet Glob Health"},{"key":"1282_CR7","unstructured":"Global programme to eliminate lymphatic filariasis: progress report, 2022. Geneva, World Health Organization. Weekly epidemiological record. No. 41, 98, 489\u2013502. 2023. https:\/\/iris.who.int\/bitstream\/handle\/10665\/373356\/WER9841-eng-fre.pdf?sequence=1. Accessed 10 Oct 2024."},{"key":"1282_CR8","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S1473-3099(05)70192-4","volume":"5","author":"DJ Tisch","year":"2005","unstructured":"Tisch DJ, Michael E, Kazura JW. Mass chemotherapy options to control lymphatic filariasis: a systematic review. Lancet Infect Dis. 2005;5:514\u201323.","journal-title":"Lancet Infect Dis"},{"key":"1282_CR9","unstructured":"World Health Organization. Guideline: alternative mass drug administration regimens to eliminate lymphatic filariasis. World Health Organization. License: CC BY-NC-SA 3.0 IGO. 2017. https:\/\/apps.who.int\/iris\/handle\/10665\/259381. Accessed 15 Oct 2024."},{"key":"1282_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13071-017-2044-5","volume":"10","author":"SM Njenga","year":"2017","unstructured":"Njenga SM, Kanyi HM, Mutungi FM, Okoyo C, Matendechero HS, Pullan RL, et al. Assessment of lymphatic filariasis prior to re-starting mass drug administration campaigns in coastal Kenya. Parasit Vectors. 2017;10:99.","journal-title":"Parasit Vectors"},{"key":"1282_CR11","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/cid\/civ882","volume":"62","author":"EK Thomsen","year":"2016","unstructured":"Thomsen EK, Sanuku N, Baea M, Satofan S, Maki E, Lombore B, et al. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis. Clin Infect Dis. 2016;62:334\u201341.","journal-title":"Clin Infect Dis"},{"key":"1282_CR12","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","volume":"379","author":"CL King","year":"2018","unstructured":"King CL, Suamani J, Sanuku N, Cheng YC, Satofan S, Mancuso B, et al. A trial of a triple-drug treatment for lymphatic filariasis. N Engl J Med. 2018;379:1801\u201310.","journal-title":"N Engl J Med"},{"key":"1282_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0011942","volume":"18","author":"SM Njenga","year":"2024","unstructured":"Njenga SM, Kanyi H, Okoyo C, Githinji E, Mwatele C, Matendechero SH, et al. Triple-drug therapy with ivermectin, diethylcarbamazine and albendazole for the acceleration of lymphatic filariasis elimination in Kenya: programmatic implementation and results of the first impact assessment. PLoS Negl Trop Dis. 2024;18: e0011942.","journal-title":"PLoS Negl Trop Dis"},{"key":"1282_CR14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/ph15050594","volume":"15","author":"AM Fimbo","year":"2022","unstructured":"Fimbo AM, Minzi OM, Mmbando BP, Gurumurthy P, Kamuhabwa AAR, Aklillu E. Safety and tolerability of ivermectin and albendazole mass drug administration in lymphatic filariasis endemic communities of Tanzania: a cohort event monitoring study. Pharmaceuticals (Basel, Switzerland). 2022;15:594.","journal-title":"Pharmaceuticals (Basel, Switzerland)."},{"key":"1282_CR15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/ph14030264","volume":"14","author":"C Khaemba","year":"2021","unstructured":"Khaemba C, Barry A, Omondi WP, Bota K, Matendechero S, Wandera C, et al. Safety and tolerability of mass diethylcarbamazine and albendazole administration for the elimination of lymphatic filariasis in Kenya: an active surveillance study. Pharmaceuticals (Basel, Switzerland). 2021;14:264.","journal-title":"Pharmaceuticals (Basel, Switzerland)."},{"key":"1282_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006454","volume":"12","author":"PJ Budge","year":"2018","unstructured":"Budge PJ, Herbert C, Andersen BJ, Weil GJ. Adverse events following single dose treatment of lymphatic filariasis: observations from a review of the literature. PLoS Negl Trop Dis. 2018;12: e0006454.","journal-title":"PLoS Negl Trop Dis"},{"key":"1282_CR17","first-page":"315","volume":"78","author":"World Health Organization","year":"2003","unstructured":"World Health Organization. Report on active surveillance for adverse events following the use of drug co-administrations in the global programme to eliminate lymphatic filariasis. Wkly Epidemiol Rec. 2003;78:315\u20137.","journal-title":"Wkly Epidemiol Rec"},{"key":"1282_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2883-1-1","volume":"1","author":"S Pani","year":"2002","unstructured":"Pani S, Subramanyam Reddy G, Das L, Vanamail P, Hoti S, Ramesh J, et al. Tolerability and efficacy of single dose albendazole, diethylcarbamazine citrate (DEC) or co-administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital-based study. Filaria J. 2002;1:1.","journal-title":"Filaria J"},{"key":"1282_CR19","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s40264-023-01338-9","volume":"46","author":"C Khaemba","year":"2023","unstructured":"Khaemba C, Barry A, Omondi WP, Kirui E, Oluka M, Parthasarathi G, et al. Comparative safety surveillance of triple (IDA) versus dual therapy (DA) in mass drug administration for elimination of lymphatic filariasis in Kenya: a cohort event monitoring study. Drug Saf. 2023;46:961\u201374.","journal-title":"Drug Saf"},{"key":"1282_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010096","volume":"16","author":"L Tavul","year":"2022","unstructured":"Tavul L, Laman M, Howard C, Kotty B, Samuel A, Bjerum C, et al. Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: an open-label, cluster-randomised trial. PLoS Negl Trop Dis. 2022;16: e0010096.","journal-title":"PLoS Negl Trop Dis"},{"key":"1282_CR21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1086\/315735","volume":"182","author":"M Haarbrink","year":"2000","unstructured":"Haarbrink M, Abadi GK, Buurman WA, Dentener MA, Terhell AJ, Yazdanbakhsh M. Strong association of interleukin-6 and lipopolysaccharide-binding protein with severity of adverse reactions after diethylcarbamazine treatment of microfilaremic patients. J Infect Dis. 2000;182:564\u20139.","journal-title":"J Infect Dis"},{"key":"1282_CR22","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1093\/infdis\/164.4.814","volume":"164","author":"GJ Weil","year":"1991","unstructured":"Weil GJ, Lammie PJ, Richards FO Jr, Eberhard ML. Changes in circulating parasite antigen levels after treatment of bancroftian filariasis with diethylcarbamazine and ivermectin. J Infect Dis. 1991;164:814\u20136.","journal-title":"J Infect Dis"},{"key":"1282_CR23","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1093\/cid\/ciz1050","volume":"71","author":"CM Bjerum","year":"2020","unstructured":"Bjerum CM, Ouattara AF, Aboulaye M, Kouadio O, Marius VK, Andersen BJ, et al. Efficacy and safety of a single dose of ivermectin, diethylcarbamazine, and albendazole for treatment of lymphatic filariasis in Cote d\u2019Ivoire: an open-label randomized controlled trial. Clin Infect Dis. 2020;71:e68\u201375.","journal-title":"Clin Infect Dis"},{"key":"1282_CR24","unstructured":"Ministry of Health (MOH) Kenya: Department of preventive and promotive health. Training manual for lymphatic filariasis mass drug administration. 2018."},{"key":"1282_CR25","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3390\/jcm9051550","volume":"9","author":"AM Fimbo","year":"2020","unstructured":"Fimbo AM, Minzi OMS, Mmbando BP, Barry A, Nkayamba AF, Mwamwitwa KW, et al. Prevalence and correlates of lymphatic filariasis infection and its morbidity following mass ivermectin and albendazole administration in Mkinga district, North-Eastern Tanzania. J Clin Med. 2020;9:1550.","journal-title":"J Clin Med"},{"key":"1282_CR26","unstructured":"Common terminology criteria for adverse events (CTCAE) version 5.0 https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_8.5x11.pdf. Accessed 15 Oct 2024."},{"key":"1282_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/JCM.00706-19","volume":"57","author":"BA Mathison","year":"2019","unstructured":"Mathison BA, Couturier MR, Pritt BS. Diagnostic identification and differentiation of microfilariae. J Clin Microbiol. 2019;57:10.","journal-title":"J Clin Microbiol"},{"key":"1282_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001930","volume":"6","author":"J Kubofcik","year":"2012","unstructured":"Kubofcik J, Fink DL, Nutman TB. Identification of Wb123 as an early and specific marker of Wuchereria bancrofti infection. PLoS Negl Trop Dis. 2012;6: e1930.","journal-title":"PLoS Negl Trop Dis"},{"key":"1282_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40249-024-01214-3","volume":"13","author":"AM Fimbo","year":"2024","unstructured":"Fimbo AM, Mnkugwe RH, Mlugu EM, Kunambi PP, Malishee A, Minzi OMS, et al. Efficacy of ivermectin and albendazole combination in suppressing transmission of lymphatic filariasis following mass administration in Tanzania: a prospective cohort study. Infect Dis Poverty. 2024;13:44.","journal-title":"Infect Dis Poverty"},{"key":"1282_CR30","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/S1473-3099(22)00026-3","volume":"22","author":"M Laman","year":"2022","unstructured":"Laman M, Tavul L, Karl S, Kotty B, Kerry Z, Kumai S, et al. Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial. Lancet Infect Dis. 2022;22:1200\u20139.","journal-title":"Lancet Infect Dis"},{"key":"1282_CR31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1046\/j.1365-3156.1996.d01-79.x","volume":"1","author":"G Dreyer","year":"1996","unstructured":"Dreyer G, Addiss D, Noroes J, Amaral F, Rocha A, Coutinho A. Ultrasonographic assessment of the adulticidal efficacy of repeat high-dose ivermectin in bancroftian filariasis. Trop Med Int Health. 1996;1:427\u201332.","journal-title":"Trop Med Int Health"},{"key":"1282_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008298","volume":"14","author":"CL Dubray","year":"2020","unstructured":"Dubray CL, Sircar AD, Beau de Rochars VM, Bogus J, Direny AN, Ernest JR, et al. Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: results from a two-armed, open-label, cluster-randomized, community study. PLoS Negl Trop Dis. 2020;14: e0008298.","journal-title":"PLoS Negl Trop Dis"},{"key":"1282_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009069","volume":"15","author":"P Jambulingam","year":"2021","unstructured":"Jambulingam P, Kuttiatt VS, Krishnamoorthy K, Subramanian S, Srividya A, Raju HKK, et al. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India. PLoS Negl Trop Dis. 2021;15: e0009069.","journal-title":"PLoS Negl Trop Dis"},{"key":"1282_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003753.pub3:CD003753","author":"J Critchley","year":"2005","unstructured":"Critchley J, Addiss D, Gamble C, Garner P, Gelband H, Ejere H, et al. Albendazole for lymphatic filariasis. Cochrane Database Syst Rev. 2005. https:\/\/doi.org\/10.1002\/14651858.CD003753.pub3:CD003753.","journal-title":"Cochrane Database Syst Rev"},{"key":"1282_CR35","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.2147\/DDDT.S97088","volume":"10","author":"D Colombo","year":"2016","unstructured":"Colombo D, Zagni E, Nica M, Rizzoli S, Ori A, Bellia G. Gender differences in the adverse events\u2019 profile registered in seven observational studies of a wide gender-medicine (MetaGeM) project: the MetaGeM safety analysis. Drug Des Devel Ther. 2016;10:2917\u201327.","journal-title":"Drug Des Devel Ther"},{"key":"1282_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","volume":"11","author":"I Zucker","year":"2020","unstructured":"Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11:32.","journal-title":"Biol Sex Differ"},{"key":"1282_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.10.001","volume":"17","author":"S Watson","year":"2019","unstructured":"Watson S, Caster O, Rochon PA, den Ruijter H. Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a century. EClinicalMedicine. 2019;17: 100188.","journal-title":"EClinicalMedicine"},{"key":"1282_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.11.009","volume":"17","author":"M Lapeyre-Mestre","year":"2019","unstructured":"Lapeyre-Mestre M. Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies. EClinicalMedicine. 2019;17: 100216.","journal-title":"EClinicalMedicine"},{"key":"1282_CR39","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4269\/ajtmh.1994.50.206","volume":"50","author":"JP Moulia-Pelat","year":"1994","unstructured":"Moulia-Pelat JP, Nguyen LN, Glaziou P, Chanteau S, Ottesen EA, Cardines R, et al. Ivermectin plus diethylcarbamazine: an additive effect on early microfilarial clearance. Am J Trop Med Hyg. 1994;50:206\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"1282_CR40","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s12639-019-01126-2","volume":"43","author":"PV Sadarama","year":"2019","unstructured":"Sadarama PV, Chirayath D, Pillai UN, Lakshmanan B. Comparison of efficacy of ivermectin and diethylcarbamazine against naturally infected Brugia malayi microfilaria in dogs. J Parasit Dis. 2019;43:554\u20139.","journal-title":"J Parasit Dis"}],"container-title":["Infectious Diseases of Poverty"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-025-01282-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40249-025-01282-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-025-01282-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T10:19:58Z","timestamp":1740392398000},"score":1,"resource":{"primary":{"URL":"https:\/\/idpjournal.biomedcentral.com\/articles\/10.1186\/s40249-025-01282-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1282"],"URL":"https:\/\/doi.org\/10.1186\/s40249-025-01282-z","relation":{},"ISSN":["2049-9957"],"issn-type":[{"value":"2049-9957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received ethical approval from the Kenyatta National Hospital-University of Nairobi Ethics and Research Committee (Ref No: KNH-ERC\/A\/413). Written informed consent and\/or assent were obtained from adults, parents, or legal guardians of children before study enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}